How Dangerous Is Percutaneous Heart Valve Replacement Surgery?
Title: How Dangerous Is Percutaneous Heart Valve Replacement Surgery?Category: Procedures and TestsCreated: 5/14/2020 12:00:00 AMLast Editorial Review: 5/14/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - May 14, 2020 Category: Cardiology Source Type: news
Best Practices for Human-Centric Design of Medical Devices
Medical devices designed to accommodate human variability present a growing opportunity for the healthcare and life sciences industries. Historically, medicine has solved many of the “simple†issues first: how to fix a broken leg has been known for centuries! But today we have treatments that didn’t even exist a generation ago, such as the use of stents and replacement valves for heart disease. These devices address a more limited cohort of people and are most successful when designed to be patient-specific. The cohorts themselves must also be further defined to account...
Source: MDDI - May 5, 2020 Category: Medical Devices Authors: Kristian Debus Tags: Design Source Type: news
CT helps predict TAVR outcomes
Identifying fibrotic lung disease on CT before transcathetor aortic valve replacement...Read more on AuntMinnie.comRelated Reading:
4D CT sheds light on post-TAVR treatment strategies
3D printing technique improves heart valve sizing
3D-printed aortas could work well for TAVR
3D printing helps evaluate leaks after TAVR procedures
CT better than echo for aortic annulus before TAVR (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 4, 2020 Category: Radiology Source Type: news
Edwards Lifesciences Drops 2020 Revenue Guidance Due to COVID-19
While Edwards Lifesciences reported first-quarter sales growth of 14%, the structural heart company saw a steep drop in procedure volume in the last few weeks of the quarter due to COVID-19.
"As you might expect, procedure volumes in March varied greatly by geography, even by hospital, as patients and providers turned their focus to the pandemic," CEO Mike Mussallem said during the company's first-quarter earnings call, according to a SeekingAlpha transcript.
Mussallem said the company expects the impact of COVID-19 on its transcatheter aortic valve replacement (TAVR) sales to be most severe in the second quarter, followed...
Source: MDDI - April 25, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news
With a heavy heart: How men and women develop heart disease differently
(McGill University) A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2020 Category: International Medicine & Public Health Source Type: news
Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners to Continue Clinical Trials With Its Leaflex(TM) Aortic Valve Technology
REHOVOT, Israel, April 20, 2020 -- (Healthcare Sales & Marketing Network) -- Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million rou... Devices, Interventional, Cardiology, Venture Capital Pi-Cardia, Leaflex Performer, Leaflex, heart valve calcification (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 20, 2020 Category: Pharmaceuticals Source Type: news
Catheter-Based Solution Being Developed to Treat Heart Valve Calcification
Pi-Cardia Ltd. has raised $27 million to develop a catheter-based solution to treat heart valve calcification. The Rehovot, Israel-based company said the financing was led by Sonfinnova Partners and joined by Professor Jacques Séguin, Chairman of the company, with further participation from existing investors.
The financing follows the successful completion of the company’s First-In-Human studies of the Leaflex Catheter.
Pi-Cardia said its technology performs mechanical scoring of valve calcification, restoring leafelts’ mobility and improving valve hemodynamics. The company...
Source: MDDI - April 20, 2020 Category: Medical Devices Authors: MDDI Staff Tags: Business Cardiovascular Source Type: news
PET/CT pinpoints Hodgkin's lymphoma treatment response
PET/CT significantly outperformed CT alone in predicting treatment response...Read more on AuntMinnie.comRelated Reading:
FDG-PET leads prediction on neuroendocrine tumor outcomes
IMV: PET scan volume continues growing at steady pace
FDG-PET/CT points to cervical cancer patient outcomes
FDG-PET/CT within a year of heart valve surgery looks safe
PET/CT beats SPECT for neuroendocrine tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 20, 2020 Category: Radiology Source Type: news
TAVR equivalent to surgery at 2 years among low-risk patients
(American College of Cardiology) Patients undergoing transcatheter aortic valve replacement (TAVR) fared equally well compared with those undergoing open heart valve replacement surgery in terms of the combined risk of death, stroke or rehospitalization at two years, the primary endpoint of the PARTNER 3 trial being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
TAVR found non-inferior to surgery in broad patient population
(American College of Cardiology) Patients who underwent transcatheter aortic valve replacement (TAVR) did not have a higher rate of death at one year compared with those who had their heart valve replaced via open-heart surgery, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
TAVR Device Orientation May Reduce Coronary Overlap TAVR Device Orientation May Reduce Coronary Overlap
Initial orientation of transcatheter heart valves may potentially preserve coronary access, a study suggests.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
3D printing improves accuracy of knee arthroplasty
A new technique that relies on 3D-printed surgical guides designed with CT...Read more on AuntMinnie.comRelated Reading:
Can ultrasound, 3D printing deepen maternal-fetal bonds?
Can 3D printing help optimize cardiac CT protocols?
3D printing may improve safety of upper GI surgery
3D-printed head customizes neurosurgery simulation
3D printing technique improves heart valve sizing (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 3, 2020 Category: Radiology Source Type: news
AHA News: When an Untreated Infection Leads to Heart Valve Disease
Title: AHA News: When an Untreated Infection Leads to Heart Valve DiseaseCategory: Health NewsCreated: 2/24/2020 12:00:00 AMLast Editorial Review: 2/25/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 25, 2020 Category: Cardiology Source Type: news
